A Phase II Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Multiple Myeloma Patients
3.1.1 Stage II-III multiple myeloma or have progression after initial treatment of Stage I
disease (Durie Salmon Staging). Patients with plasma cell leukemia are also included.
3.1.2 Pathology reviewed and the diagnosis confirmed at Stanford University Medical
3.1.3 Age > 18 years and <= 75 years.
3.1.4 Karnofsky Performance Status > 70%.
3.1.5 Corrected DLCO > 60%
3.1.6 Left ventricle ejection fraction (LVEF) > 50%.
3.1.7 ALT and AST must be <= 2X normal. Total bilirubin <= 2 mg/dL unless hemolysis or
3.1.8 Estimated creatinine clearance > 50 ml/min.
3.1.9 Have a related or unrelated HLA-identical donor or one antigen/allele mismatched in
HLA-A, B, C or DRB1.
3.1.10 Signed informed consent.
3.3 Donor Evaluation Inclusion Criteria
3.3.1 Age >=17.
3.3.2 HIV seronegative
3.3.3 Donor must be capable of giving signed, informed consent
3.3.4 No contraindication to the administration of G-CSF
3.3.5 Willing to have a central venous catheter placed for apheresis if peripheral veins
3.2.1 Prior allogeneic hematopoietic cell transplantation.
3.2.2 Uncontrolled active infection.
3.2.4 Uncontrolled congestive heart failure or angina.
3.2.5 Pregnancy or nursing patients will be excluded from the study.
3.2.6 Those who are HIV-positive will be excluded from the study due to high risk of
lethal infection after hematopoietic cell transplantation.
3.4 Donor Evaluation Exclusion Criteria
3.4.1 Serious medical or psychological illness.
3.4.2 Pregnant or lactating women are not eligible
3.4.3 Prior malignancies within the last 5 years except for non-melanoma skin cancers